Pharmaceutical Research Co., Ltd. (CEO Shin-gyu Kim, Ki-seok Kang) announced on the 20th of this month it has acquired a patent in China for a composition that exhibits a continuous skin enhancement effect.

The title of the patent invention is "Filling composition for tissue enhancement containing nucleic acid, chitosan and hyaluronic acid." The patent boasts a feature where when the composition is injected into a necessary area, the volume of the filler increases while new tissues are created, showing excellent durability.

An official from PharmaResearch said, "Amid the rapid increase in anti-aging demand, we have developed an aesthetic composition through our own technology. The patent guarantees our exclusive rights from China until July 2036," he said.

Meanwhile, PharmaResearch is a regenerative medicine-based pharmaceutical bio company that manufactures and sells pharmaceuticals, medical devices, cosmetics, and health functional foods, focusing on tissue regeneration materials DOT(TM) PDRN and DOT(TM) PN.

Their brands include Rejuran, Conjuran, Rejuran Cosmetics, and Lian Eye Drops.

Media Contact

Company Name: PharmaResearch

Contact Person: Seulki Kwak

Email: skkwak@pharmaresearch.co.kr

Phone: +82-31-8039-1422

City: Gangneung-si

State: Gangwon-do

Country: South Korea

Website: http://pharmaresearch.co.kr/eng

Source: www.abnewswire.com

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE